

CAN WE FINE-TUNE MICROBIOME WITH PROBIOTICS?

M. Fiorani, S. Porcari, S. Bibbò, G. Cammarota, G. Ianiro

Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy; UOC Gastroenterologia and UOC CEMAD Medicina Interna e Gastroenterologia, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Corresponding Author: Marcello Fiorani, MD; e-mail: marcellofiorani94@gmail.com

Abstract – The therapeutic modulation of gut microbiota is a rapidly growing field of research, recognized as pivotal in the development of personalized medicine. In this context, probiotics have emerged as one of the main therapeutic tools, with increasing evidence supporting their efficacy in different clinical areas. In this review, we summarize the most relevant updates published during the past year regarding the use of probiotics in the management of various gastrointestinal and extraintestinal disorders.

Keywords: Probiotics, Gut microbiota, Irritable bowel syndrome.

INTRODUCTION

Gut microbiota is a dynamic collection of microorganisms, composed of trillions of microbes, both prokaryotes (bacteria and archaea), and eukaryotes (fungi, protozoa, and helminths), in addition to viruses¹, that coevolved alongside the human hosts². Its taxonomic composition is highly variable between individuals due to multiple factors, such as dietary habits, lifestyle, genetics, environmental factors, and the microbiome's intrinsic interaction structure³. Numerous studies have confirmed that gut microbiota is involved in maintaining physiological homeostasis, influencing several key functions such as nutrient absorption, immune system regulation, and protection against pathogens^{4,5}. On the other hand, the alteration of the composition and function of gut microbiota, with the disruption of homeostasis, has been associated with several disorders, including gastrointestinal⁶, metabolic⁷, neurological disorders⁸, and cancer⁹.

Hence, therapeutic approaches that modulate gut microbiota can potentially be applied to a wide range of clinical conditions, allowing the development of personalized therapeutic or prophylactic treatments. Moreover, other relevant fields of application are the prevention of chronic diseases¹⁰, the improvement of the nutritional status of the host¹¹, and the modulation of the host's response to medical therapies^{12,13}.

Even though our knowledge of the human microbiota continues to grow, its clinical application is still in an early stage. The therapeutic strategies that are currently available have different aims and mechanisms of action, and while certain approaches, such as nutritional interventions or fecal microbiota transplantation (FMT), have a broad impact on the entire microbial community, others, such as probiotics, prebiotics, postbiotics, and phage therapy, can act more precisely on specific taxa or strains¹².

Beneficial taxa can be supplemented through the use of probiotics, which are defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the



This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/)

host¹⁴, and they have been extensively studied in recent years, in the context of numerous clinical disorders¹⁵. The main available probiotics are bacteria, such as Bifidobacteria, Lactobacilli, Streptococci, and particular strains of *E. coli*, or yeasts such as *Saccharomyces boulardii*^{16,17}. Probiotics can exert their effect through different mechanisms, including the production of substrates, like short-chain fatty acids (SCFA), the improvement of intestinal barrier function, and the inhibition of the growth of opportunistic pathogens¹⁸.

However, the definition of probiotics includes many products with different and often scarcely specified characteristics, allowing questionable generalizations. Consequently, the evidence for probiotic use is still insufficient in numerous conditions where they could be potentially employed¹⁹.

In 2012, in order to address these issues, the FDA defined the new category of live biotherapeutic products (LBP)²⁰. LBPs are products containing live microorganisms, applicable to the prevention, treatment, or cure of a disease or condition in human beings^{20,21}. Notably, LBPs are more precisely regulated, supporting the identification of specific indications for each probiotic strain as evidenced by clinical studies, which is essential for the progress of personalized medicine²².

The therapeutic modulation of the gut microbiota through probiotics is, therefore, a highly significant field of research, and this review summarizes the most important advancements in this area published over the past year.

PROBIOTICS IN GASTROINTESTINAL DISORDERS

Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by a high prevalence and often associated with psychological comorbidities²³. A randomized, double-blinded, placebo-controlled study²⁴ included 70 female patients affected by IBS and observed that the administration of a multistrain probiotic containing *Lactobacillus acidophilus* CUL60, *Lactobacillus acidophilus* CUL21, *Bifidobacterium bifidum* CUL20 and *Bifidobacterium animalis* subsp. *lactis* CUL34 significantly reduced the IBS-symptom severity score (IBS-SSS), anxiety and depression scores, and the IBS-related control and avoidance behavior score. The fecal microbiota showed significant differences in the abundance of *Roseburia*, *Holdemanelia*, *Blautia*, *Agathobacter*, *Ruminococcus*, *Prevotella*, *Bacteroides*, and *Anaerostipes*. Another multi-center randomized controlled trial (RCT), comprising 317 patients with IBS-D, investigated the efficacy of *Lactiplantibacillus plantarum* Lpla33 and showed that after 8 weeks, the IBS-SSS was significantly reduced²⁵.

Srivastava et al²⁶ observed that *Bifidobacterium longum* CECT 7347 reduced the IBS-SSS and improved the quality of life of IBS-D patients, compared to placebo. Interestingly, a post-biotic obtained from the same strain was similarly effective. Other studies investigated the factors potentially associated with response to probiotics, finding that IBS-D patients with high abdominal pain scores could be more likely to respond to probiotic therapies²⁷. Specific taxa could also predict probiotic efficacy: in particular, *Collinsella aerofaciens* appeared to be over-represented in responder IBS patients²⁸.

Chronic constipation (CC) is another common gastrointestinal disorder, and various evidence suggests that dysbiosis plays a significant role in its pathogenesis²⁹. A randomized, double-blind, placebo-controlled study, including 163 patients, evaluated the effect of *Lactiplantibacillus plantarum* P9 on CC³⁰. The probiotic treatment improved the frequency of spontaneous bowel movements and complete spontaneous bowel movements and reduced the level of worries and concerns. The administration of *Lactiplantibacillus plantarum* P9 was associated with favorable changes in the fecal metabolome and with the enrichment of beneficial taxa, such as *Lactiplantibacillus plantarum* and *Ruminococcus_B gnavus*. The incidence of chronic constipation increases with age, and it has been shown that elderly subjects have a reduced abundance of bifidobacteria³¹. A Japanese RCT³² examined the efficacy of *Bifidobacterium longum* BB536 in 79 elderly patients affected by CC, observing an improvement in the number of bowel movements.

Parkinson's disease (PD) is often associated with constipation, and its prevalence increases with the progression of the disease, reducing the patient's quality of life³³. Constipation could be associated with gut microbiota alterations, as it has been described that in PD patients

there is a decreased abundance of Lachnospiraceae and Prevotellaceae, while Verrucomicrobiaceae are increased^{34,35}. *Lacticaseibacillus paracasei* strain Shirota has shown encouraging results in a previous pilot study, improving stool consistency and defecation habits in PD patients³⁶. These results have been confirmed by a recent RCT by Yang et al³⁷ who evaluated the effect of the administration of this strain in PD patients, observing a favorable effect on constipation-related symptoms.

Functional dyspepsia (FD) is a highly prevalent chronic disorder of gut-brain interaction, whose numerous pathophysiological mechanisms appear to be also associated with dysbiosis³⁸. An RCT by Zhang et al³⁹ observed that the treatment with *Bifidobacterium animalis* subsp. *lactis* BL-99 for 8 weeks significantly improved the clinical response in FD patients, but the effect disappeared after 8 weeks from the end of the therapy. Interestingly, the authors reported an increased abundance of SCFA-producing microbiota and augmented levels of fecal and serum SCFA.

Another important cause of dyspeptic symptoms is *Helicobacter pylori* (Hp) infection⁴⁰. A study by Niu et al⁴¹ investigated the effect of *Lacticaseibacillus rhamnosus* LRa05 on the Hp eradication rate and the mitigation of the gastrointestinal side effects related to the bismuth quadruple therapy. Probiotic supplementation was associated with a non-significant trend toward a better eradication rate and a significant reduction of gastrointestinal symptoms. An additional study showed that *Lactobacillus rhamnosus* GG improved the remission of dyspepsia in HP patients who underwent bismuth quadruple therapy without significant differences in eradication rates and therapy-associated side effects⁴².

PROBIOTICS IN EXTRAINTESTINAL DISORDERS

The gut-liver axis has been implicated in the pathogenesis and the progression of numerous liver diseases, outlining the relevant role of the intestinal barrier and dysbiosis⁴³. The most common cause of chronic liver disease worldwide is metabolic-associated fatty liver disease (MAFLD)⁴⁴, known to be associated with microbiota alterations, including an increase in Proteobacteria⁴⁵. A clinical study by Lin et al⁴⁶ examined the effect of different combinations of probiotics (comprising *L. fermentum* TSF331, *L. reuteri* TSR332, and *L. plantarum* TSP05) in patients with elevated baseline levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and uric acid (UA). After 60 days, the authors observed that in all the treatment groups, the serum levels of AST, ALT, and UA levels were significantly reduced. Another trial⁴⁷ examined patients affected by histology-proven nonalcoholic steatohepatitis (NASH) and showed that the administration of *Lactobacillus acidophilus* ATCC SD5221 and *Bifidobacterium lactis* HN019 reduced the AST to platelet ratio index (APRI score). Alcohol-associated liver disease (ALD) is often diagnosed in heavy drinkers, but currently, there is a shortage of effective therapeutic options. In a pilot study, *Lactobacillus rhamnosus* GG showed encouraging results, reducing the markers of liver injury and alcohol intake⁴⁸. Probiotic therapies could also be effective in cirrhotic patients referred for liver transplantation, as shown by Ramachandran et al⁴⁹. A multistrain probiotic was associated with improvements in the nutritional status and with a significant reduction of the Child Turcotte Pugh score of these patients.

The incidence of metabolic disorders and obesity has increased substantially in the last decades due to many factors, including increased food consumption and a sedentary lifestyle⁵⁰. Gut microbiota is known to contribute to the pathogenesis of various metabolic disorders, regulating different mechanisms such as glucose and lipid metabolism, energy absorption, and chronic inflammation^{51,52}. *Lacticaseibacillus paracasei* has shown beneficial effects in several murine models of metabolic disorders⁵³, and an RCT by Yang et al⁵⁰ evaluated its effects on endothelial function and cardiometabolic health in patients affected by metabolic syndrome. Probiotic supplementation resulted in improved endothelial function, potentially due to the reduction of remnant cholesterol levels. Regarding diabetes, a multi-strain probiotic containing *Lactobacillus acidophilus*, *Lactobacillus plantarum*, *Saccharomyces boulardii*, and *Bifidobacterium lactis*, led to encouraging results in 91 diabetic patients who received the probiotic treatment or placebo for 6 months. Compared to controls, the patients who received the multi-strain probiotic showed significantly lower levels of total cholesterol, fasting blood glucose, and HbA1c⁵⁴.

Metformin is a cornerstone drug in the treatment of diabetes and is widely prescribed. One of the most significant issues associated with its use is the occurrence of gastrointestinal side effects, affecting up to 20% of patients⁵⁵. A randomized, double-blind, cross-over trial⁵⁶ assessed the effectiveness of a multi-strain probiotic containing *Bifidobacterium bifidum* W23, *Bifidobacterium lactis* W51, *Bifidobacterium lactis* W52, *Lactobacillus acidophilus* W37, *Levilactobacillus brevis* W63, *Lacticaseibacillus casei* W56, *Ligilactobacillus salivarius* W24, *Lactococcus lactis* W19, and *Lactococcus lactis* W58 in 37 diabetic patients with gastrointestinal side effects due to metformin treatment. The authors observed that the probiotic supplementation was associated with a significant reduction of nausea, abdominal bloating, abdominal pain, and diarrhea, together with an improvement in self-assessed tolerability of metformin⁵⁶.

The bidirectional and continuous relationship between the gut and the central nervous system is known as the gut-brain axis, and the recognition of the role of gut microbiota in their communication led to the concept of the microbiota-gut-brain axis. Gut microbiota modulates the gut-brain axis in multiple ways, including through endocrine, immune, and neural pathways. Numerous microbes are known to synthesize neurotransmitters, such as GABA, noradrenaline, and dopamine. Moreover, gut microbiota can produce neuroactive metabolites that influence behavior and neural activity through mechanisms still being explored⁵⁷.

Major depressive disorder (MDD) is one of the main causes of disability around the world⁵⁸, but its treatment still poses significant challenges, as almost one-third of patients receiving pharmacotherapy or psychotherapy achieve only partial remission from MDD⁵⁹. A pilot RCT evaluated 49 patients affected by MDD with incomplete response to antidepressant medication and showed that a multi-strain probiotic combined with the ongoing antidepressant medication led to greater improvements in depressive and anxiety symptoms compared with placebo⁶⁰.

The neural mechanisms underlying the clinical effects of probiotics in MDD are still unknown, and to investigate these effects, a study used a multimodal neuroimaging approach in 32 patients affected by MDD receiving a probiotic treatment or placebo. Probiotics appeared to prevent neuronal degeneration along the uncinate fasciculus and to change fronto-limbic resting-state functional connectivity, and these structural and functional changes were associated with improved depressive symptoms⁶¹.

Psychobiotics are also investigated in the management of anxiety. Test anxiety among college students is a very common issue, and a study by Zhu et al⁶² investigated the effects of *Lactobacillus plantarum* JYLP-326 on this condition. The probiotic supplementation improved the symptoms of anxiety, depression, and insomnia, together with favorable changes in the patient's gut microbiota profile.

Psychosocial stress is a well-known risk factor for different mood disorders, including sleep disorders or depression⁶³. *Bifidobacterium longum* (BL) NCC3001 could have beneficial effects on stress-related symptoms, as shown by a recent study where healthy adults with mild-to-moderate stress received this probiotic therapy for 6 weeks, improving their sleep quality and reducing the perceived stress⁶⁴. *Bifidobacterium breve* M-16V could also be effective in improving mood and sleep in patients with high anxiety levels, probably through the increase of piperacolic acid levels. This metabolite is involved in the GABA system and is known to be associated with beneficial effects on depression and anxiety symptoms⁶⁵.

Probiotic therapies could also be helpful in the management of neurological disorders, such as multiple sclerosis. In a randomized clinical trial by Asghari et al⁶⁶, *Saccharomyces boulardii* supplementation for 4 months reduced the inflammatory markers and the oxidative stress indicators while improving the quality of life, pain, and fatigue severity compared to placebo in MS patients.

CONCLUSIONS

During the past year, new data have consolidated the role of probiotics in the management of numerous disorders. As the field of microbiota modulation continues to develop, the use of probiotics and other therapeutic microbiome modulators is expected to gain a central role in the future of medicine. Nevertheless, high-quality and rigorous studies are necessary to further improve the efficacy and specificity of probiotic treatments.

Conflict of Interest

GI has received personal fees for acting as a speaker for Alfa Sigma, Biocodex, Illumina, Malesci, Sofar, and Tillotts Pharma and personal fees for acting as a consultant or advisor for Biocodex, Malesci, and Tillotts Pharma. GC has received personal fees for acting as an advisor for Ferring Therapeutics. All other authors declare no competing interests.

Authors' Contributions

Writing - original draft preparation: M. Fiorani. Supervision: G. Ianiro, S. Porcari, S. Bibbò, G. Cammarota. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

The authors thank Fondazione Roma (Italy) for their continuous support of our scientific research.

ORCID ID

M. Fiorani: 0000-0001-7005-6147

S. Porcari: 0000-0003-0085-3954

S. Bibbò: 0000-0002-8043-4807

G. Cammarota: 0000-0002-8043-4807

G. Ianiro: 0000-0002-8318-0515

Ethics Statement

Not applicable due to the type of study.

AI Disclosure

The authors used no AI tools for the conceiving and writing of the manuscript.

REFERENCES

1. Dogra SK, Doré J, Damak S. Gut Microbiota Resilience: Definition, Link to Health and Strategies for Intervention. *Front Microbiol* 2020; 11: 572921.
2. Dominguez-Bello MG, Godoy-Vitorino F, Knight R, Blaser MJ. Role of the microbiome in human development. *Gut* 2019; 68: 1108-1114.
3. Schmidt TSB, Raes J, Bork P. The Human Gut Microbiome: From Association to Modulation. *Cell* 2018; 172: 1198-1215.
4. Ting NL, Lau HC, Yu J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. *Gut* 2022; 71: 1412-1425.
5. Gebrayel P, Nicco C, Al Khodor S, Bilinski J, Caselli E, Comelli EM, Egert M, Giaroni C, Karpinski TM, Loniewski I, Mulak A, Reygnier J, Samczuk P, Serino M, Sikora M, Terranegra A, Ufnal M, Villegier R, Pichon C, Konturek P, Edeas M. Microbiota medicine: towards clinical revolution. *J Transl Med* 2022; 20: 111.
6. Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol* 2020; 17: 223-237.
7. Zhang Z, Mocanu V, Cai C, Dang J, Slater L, Deehan EC, Walter J, Madsen KL. Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome-A Systematic Review. *Nutrients* 2019; 11: 2291.
8. Mitrea L, Nemeş SA, Szabo K, Teleky BE, Vodnar DC. Guts Imbalance Imbalances the Brain: A Review of Gut Microbiota Association With Neurological and Psychiatric Disorders. *Front Med (Lausanne)* 2022; 9: 813204.
9. Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, Torino F, Banna GL, Tonini G, Libra M. Gut Microbiota and Cancer: From Pathogenesis to Therapy. *Cancers (Basel)* 2019; 11: 38.
10. Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, Fuchs CS, Willett WC, Richter JM, Chan AT. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. *Gastroenterology* 2013; 145: 970-977.

11. Chen RY, Mostafa I, Hibberd MC, Das S, Mahfuz M, Naila NN, Islam MM, Huq S, Alam MA, Zaman MU, Raman AS, Webber D, Zhou C, Sundaresan V, Ahsan K, Meier MF, Barratt MJ, Ahmed T, Gordon JI. A Microbiota-Directed Food Intervention for Undernourished Children. *N Engl J Med* 2021; 384: 1517-1528.
12. Hitch TCA, Hall LJ, Walsh SK, Leventhal GE, Slack E, de Wouters T, Walter J, Clavel T. Microbiome-based interventions to modulate gut ecology and the immune system. *Mucosal Immunol* 2022; 15: 1095-1113.
13. Klünemann M, Andrejev S, Blasche S, Mateus A, Phapale P, Devendran S, Vappiani J, Simon B, Scott TA, Kafkia E, Konstantinidis D, Zirngibl K, Mastorilli E, Banzhaf M, Mackmull MT, Hövelmann F, Nesme L, Brochado AR, Maier L, Bock T, Periwal V, Kumar M, Kim Y, Tramontano M, Schultz C, Beck M, Hennig J, Zimmermann M, Sévin DC, Cabreiro F, Savitski MM, Bork P, Typas A, Patil KR. Bioaccumulation of therapeutic drugs by human gut bacteria. *Nature* 2021; 597: 533-538.
14. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol* 2014; 11: 506-514.
15. Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. *Nat Med* 2019; 25: 716-729.
16. de Vrese M, Schrezenmeier J. Probiotics, prebiotics, and synbiotics. *Adv Biochem Eng Biotechnol* 2008; 111: 1-66.
17. Elangovan A, Allegritti JR, Fischer M. Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. *Expert Opin Biol Ther* 2019; 19: 1343-1355.
18. Derrien M, van Hylckama Vlieg JE. Fate, activity, and impact of ingested bacteria within the human gut microbiota. *Trends Microbiol* 2015; 23: 354-366.
19. Porcari S, Fusco W, Spivak I, Fiorani M, Gasbarrini A, Elinav E, Cammarota G, Ianiro G. Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics. *Lancet Gastroenterol Hepatol* 2024; 9: 460-475.
20. Federal Register. Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information; Guidance for Industry. Available at: <https://www.federalregister.gov/documents/2016/07/01/2016-15664/early-clinical-trials-with-live-biotherapeutic-products-chemistry-manufacturing-and-control> (accessed Sep 8, 2024).
21. Cordaillat-Simmons M, Rouanet A, Pot B. Live biotherapeutic products: the importance of a defined regulatory framework. *Exp Mol Med* 2020; 52: 1397-1406.
22. Bibbò S, Porcari S, Del Vecchio LE, Severino A, Mullish BH, Ianiro G, Gasbarrini A, Cammarota G. Gut microbiota and immunotherapy of renal cell carcinoma. *Hum Vaccin Immunother* 2023; 19: 2268982.
23. Sperber AD. Review article: epidemiology of IBS and other bowel disorders of gut-brain interaction (DGBI). *Aliment Pharmacol Ther* 2021; 54 Suppl 1: S1-S11.
24. Mullish BH, Michael DR, Dabcheva M, Webberley TS, Coates N, John DA, Wang D, Luo Y, Plummer SF, Marchesi JR. A double-blind, randomized, placebo-controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females. *Neurogastroenterol Motil* 2024; 36: e14751.
25. Martoni CJ, Srivastava S, Damholt A, Leyer GJ. Efficacy and dose response of *Lactiplantibacillus plantarum* in diarrhea-predominant irritable bowel syndrome. *World J Gastroenterol* 2023; 29: 4451-4465.
26. Srivastava S, Basak U, Naghibi M, Vijayakumar V, Parihar R, Patel J, Jadon PS, Pandit A, Dargad RR, Khanna S, Kumar S, Day R. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live *Bifidobacterium longum* CECT 7347 (ES1) and heat-treated *Bifidobacterium longum* CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome. *Gut Microbes* 2024; 16: 2338322.
27. Bai T, Xu Z, Xia P, Feng Y, Liu B, Liu H, Chen Y, Yan G, Lv B, Yan Z, Dai N, Long Y, Wei W, Shi Z, Li X, Fang X, Gao H, Qi L, Hou X. The Short-Term Efficacy of *Bifidobacterium* Quadruple Viable Tablet in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation. *Am J Gastroenterol* 2023; 118: 1256-1267.
28. Gargari G, Mantegazza G, Cremon C, Taverniti V, Valenza A, Barbaro MR, Marasco G, Duncan R, Fiore W, Ferrari R, De Vitis V, Barbara G, Guglielmetti S. *Collinsella aerofaciens* as a predictive marker of response to probiotic treatment in non-constipated irritable bowel syndrome. *Gut Microbes* 2024; 16: 2298246.
29. Zhang S, Wang R, Li D, Zhao L, Zhu L. Role of gut microbiota in functional constipation. *Gastroenterol Rep (Oxf)* 2021; 9: 392-401.
30. Ma T, Yang N, Xie Y, Li Y, Xiao Q, Li Q, Jin H, Zheng L, Sun Z, Zuo K, Kwok LY, Zhang H, Lu N, Liu W. Effect of the probiotic strain, *Lactiplantibacillus plantarum* P9, on chronic constipation: A randomized, double-blind, placebo-controlled study. *Pharmacol Res* 2023; 191: 106755.
31. Odamaki T, Kato K, Sugahara H, Hashikura N, Takahashi S, Xiao JZ, Abe F, Osawa R. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. *BMC Microbiol* 2016; 16: 90.
32. Takeda T, Asaoka D, Nojiri S, Yanagisawa N, Nishizaki Y, Osada T, Koido S, Nagahara A, Katsumata N, Odamaki T, Xiao JZ, Ohkusa T, Sato N. Usefulness of *Bifidobacterium longum* BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial. *Am J Gastroenterol* 2023; 118: 561-568.
33. Yuan XY, Chen YS, Liu Z. Relationship among Parkinson's disease, constipation, microbes, and microbiological therapy. *World J Gastroenterol* 2024; 30: 225-237.
34. Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Canello R, Ceccarani C, Faierman S, Pinelli G, De Bellis G, Zecca L, Cereda E, Consolandi C, Pezzoli G. Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism. *Mov Disord* 2019; 34: 396-405.
35. Bedarf JR, Hildebrand F, Coelho LP, Sunagawa S, Bahram M, Goesser F, Bork P, Wüllner U. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients. *Genome Med* 2017; 9: 39. doi: 10.1186/s13073-017-0428-y. Erratum in: *Genome Med* 2017; 9: 61.

36. Cassani E, Privitera G, Pezzoli G, Pusani C, Madio C, Iorio L, Barichella M. Use of probiotics for the treatment of constipation in Parkinson's disease patients. *Minerva Gastroenterol Dietol* 2011; 57: 117-121.
37. Yang X, He X, Xu S, Zhang Y, Mo C, Lai Y, Song Y, Yan Z, Ai P, Qian Y, Xiao Q. Effect of *Lactocaseibacillus paracasei* strain Shirota supplementation on clinical responses and gut microbiome in Parkinson's disease. *Food Funct* 2023; 14: 6828-6839.
38. Tziatzios G, Gkolfakis P, Papanikolaou IS, Mathur R, Pimentel M, Giamarellos-Bourboulis EJ, Triantafyllou K. Gut Microbiota Dysbiosis in Functional Dyspepsia. *Microorganisms* 2020; 8: 691.
39. Zhang Q, Li G, Zhao W, Wang X, He J, Zhou L, Zhang X, An P, Liu Y, Zhang C, Zhang Y, Liu S, Zhao L, Liu R, Li Y, Jiang W, Wang X, Wang Q, Fang B, Zhao Y, Ren Y, Niu X, Li D, Shi S, Hung WL, Wang R, Liu X, Ren F. Efficacy of *Bifidobacterium animalis* subsp. *lactis* BL-99 in the treatment of functional dyspepsia: a randomized placebo-controlled clinical trial. *Nat Commun* 2024; 15: 227.
40. Kim YJ, Chung WC, Kim BW, Kim SS, Kim JI, Kim NJ, Yoo J, Kim SH. Is *Helicobacter pylori* Associated Functional Dyspepsia Correlated With Dysbiosis? *J Neurogastroenterol Motil* 2017; 23: 504-516.
41. Niu Y, Li J, Qian H, Liang C, Shi X, Bu S. Evaluation of efficacy and safety of *Lactocaseibacillus rhamnosus* LRa05 in the eradication of *Helicobacter pylori*: a randomized, double-blind, placebo-controlled trial. *Front Immunol* 2024; 15: 1450414.
42. Marinelli P, Scalese G, Covelli A, Ruffa A, Bedetti G, Bruno G, Severi C. *Lactobacillus rhamnosus* GG supplementation on eradication rate and dyspepsia in *Helicobacter pylori* infection treated with three-in-one bismuth quadruple therapy. *Front Microbiol* 2022; 13: 932331.
43. Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. *Nat Rev Microbiol* 2023; 21: 719-733.
44. Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, Pennisi G, Grimaudo S, Petta S. MAFLD: a multisystem disease. *Ther Adv Endocrinol Metab* 2023; 14: 20420188221145549.
45. Aron-Wisniewsky J, Vigiotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. *Nat Rev Gastroenterol Hepatol* 2020; 17: 279-297.
46. Lin JH, Lin CH, Kuo YW, Liao CA, Chen JF, Tsai SY, Li CM, Hsu YC, Huang YY, Hsia KC, Yeh YT, Ho HH. Probiotic *Lactobacillus fermentum* TSF331, *Lactobacillus reuteri* TSR332, and *Lactobacillus plantarum* TSP05 improved liver function and uric acid management-A pilot study. *PLoS One* 2024; 19: e0307181.
47. Escouto GS, Port GZ, Tovo CV, Fernandes SA, Peres A, Dorneles GP, Houde VP, Varin TV, Pilon G, Murette A, Buss C. Probiotic Supplementation, Hepatic Fibrosis, and the Microbiota Profile in Patients with Nonalcoholic Steatohepatitis: A Randomized Controlled Trial. *J Nutr* 2023; 153: 1984-1993.
48. Vatsalya V, Feng W, Kong M, Hu H, Szabo G, McCullough A, Dasarathy S, Nagy LE, Radaeva S, Barton B, Mitchell M, McClain CJ. The Beneficial Effects of *Lactobacillus* GG Therapy on Liver and Drinking Assessments in Patients with Moderate Alcohol-Associated Hepatitis. *Am J Gastroenterol* 2023; 118: 1457-1460.
49. Ramachandran G, Pottakkat B, Basu S, Mohan P. Effect of probiotics on nutritional status, biochemical parameters, and disease severity in cirrhotic patients referred for liver transplantation-A randomised double blind, placebo-controlled trial. *Clin Nutr ESPEN* 2023; 57: 703-710.
50. Yang J, Huang J, Huang Z, Xu Y, Li W, Zhu S, Zhao Y, Ye B, Liu L, Zhu J, Xia M, Liu Y. Cardiometabolic benefits of *Lactocaseibacillus paracasei* 8700:2: A randomized double-blind placebo-controlled trial. *Clin Nutr* 2023; 42: 1637-1646.
51. Liu BN, Liu XT, Liang ZH, Wang JH. Gut microbiota in obesity. *World J Gastroenterol* 2021; 27: 3837-3850.
52. Młynarska E, Wasiak J, Gajewska A, Steć G, Jasińska J, Rysz J, Franczyk B. Exploring the Significance of Gut Microbiota in Diabetes Pathogenesis and Management-A Narrative Review. *Nutrients* 2024; 16: 1938.
53. Miao ZH, Wang JN, Shen X, Zhou QQ, Luo YT, Liang HJ, Wang SJ, Qi SH, Cheng RY, He F. Long-term use of *Lactocaseibacillus paracasei* N1115 from early life alleviates high-fat-diet-induced obesity and dysmetabolism in mice. *Benef Microbes* 2022; 13: 407-416.
54. Zikou E, Dovrolis N, Dimosthenopoulos C, Gazouli M, Makrilakis K. The Effect of Probiotic Supplements on Metabolic Parameters of People with Type 2 Diabetes in Greece-A Randomized, Double-Blind, Placebo-Controlled Study. *Nutrients* 2023; 15: 4663.
55. Nabrdalik K, Skonieczna-Żydecka K, Irlík K, Hendel M, Kwiendacz H, Łoniewski I, Januszkievicz K, Gumprecht J, Lip GYH. Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials. *Front Endocrinol (Lausanne)* 2022; 13: 975912.
56. Nabrdalik K, Drożdż K, Kwiendacz H, Skonieczna-Żydecka K, Łoniewski I, Kaczmarczyk M, Wijata AM, Nalepa J, Holleman F, Nieuwdorp M, Gumprecht J. Clinical Trial: Probiotics in Metformin Intolerant Patients with Type 2 Diabetes (ProGasMet). *Biomed Pharmacother* 2023; 168: 115650.
57. Margolis KG, Cryan JF, Mayer EA. The Microbiota-Gut-Brain Axis: From Motility to Mood. *Gastroenterology* 2021; 160: 1486-1501.
58. Friedrich MJ. Depression Is the Leading Cause of Disability Around the World. *JAMA* 2017; 317: 1517.
59. Gülpen J, Brouwer ME, Geurtsen GJ, van Dis EAM, Denys DAJP, Bockting CL. Treatments for partial remission of major depressive disorder: a systematic review and meta-analysis. *BMJ Ment Health* 2023; 26: 1-9.
60. Nikolova VL, Cleare AJ, Young AH, Stone JM. Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression: A Randomized Clinical Trial. *JAMA Psychiatry* 2023; 80: 842-847.
61. Yamanbaeva G, Schaub AC, Schneider E, Schweinfurth N, Kettelhack C, Doll JPK, Mählmann L, Brand S, Beglinger C, Borgwardt S, Lang UE, Schmidt A. Effects of a probiotic add-on treatment on fronto-limbic brain structure, function, and perfusion in depression: Secondary neuroimaging findings of a randomized controlled trial. *J Affect Disord* 2023; 324: 529-538.

62. Zhu R, Fang Y, Li H, Liu Y, Wei J, Zhang S, Wang L, Fan R, Wang L, Li S, Chen T. Psychobiotic *Lactobacillus plantarum* JYLP-326 relieves anxiety, depression, and insomnia symptoms in test anxious college via modulating the gut microbiota and its metabolism. *Front Immunol* 2023; 14: 1158137.
63. James KA, Stromin JI, Steenkamp N, Combrinck MI. Understanding the relationships between physiological and psychosocial stress, cortisol and cognition. *Front Endocrinol (Lausanne)* 2023; 14: 1085950.
64. Boehme M, Rémond-Derbez N, Lerond C, Lavalle L, Keddani S, Steinmann M, Rytz A, Dalile B, Verbeke K, Van Oudenhove L, Steiner P, Berger B, Vicario M, Bergonzelli G, Colombo Mottaz S, Hudry J. *Bifidobacterium longum* subsp. *longum* Reduces Perceived Psychological Stress in Healthy Adults: An Exploratory Clinical Trial. *Nutrients* 2023; 15: 3122.
65. Mutoh N, Moriya M, Xu C, Kato K, Arai S, Iwabuchi N, Tanaka M, Jinghua Y, Itamura R, Sakatani K, Warisawa S. *Bifidobacterium breve* M-16V regulates the autonomic nervous system via the intestinal environment: A double-blind, placebo-controlled study. *Behav Brain Res* 2024; 460: 114820.
66. Asghari KM, Dolatkhah N, Ayromlou H, Mirnasiri F, Dadfar T, Hashemian M. The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial. *Sci Rep* 2023; 13: 18577.